Real World Case 12–6
Requirement 1
Merck’s 2015 balance sheet lists $13,039 million of investments as
Requirement 2
Accounting for unrealized gains and losses (both temporary and OTT):
“Investments — Investments in marketable debt and equity securities
classified as available-for-sale are reported at fair value. Fair values of the
Company’s investments are determined using quoted market prices in active
markets for identical assets or liabilities or quoted prices for similar assets or
liabilities or other inputs that are observable or can be corroborated by
observable market data for substantially the full term of the assets or
liabilities. Changes in fair value that are considered temporary are reported
net of tax in Other Comprehensive Income (OCI). For declines in the fair
value of equity securities that are considered other-than-temporary,
impairment losses are charged to Other (income) expense, net. The Company
considers available evidence in evaluating potential impairments of its
investments, including the duration and extent to which fair value is less than
cost and, for equity securities, the Company’s ability and intent to hold the
investments. For debt securities, an other-than-temporary impairment has
occurred if the Company does not expect to recover the entire amortized cost
basis of the debt security. If the Company does not intend to sell the impaired
debt security, and it is not more likely than not it will be required to sell the
debt security before the recovery of its amortized cost basis, the amount of
the other-than-temporary impairment recognized in earnings, recorded in
Other (income) expense, net, is limited to the portion attributed to credit loss.
The remaining portion of the other-than-temporary impairment related to
other factors is recognized in OCI.”